New RNA Drug RBD7022 Enters Phase 1 Testing as Next-Gen LDL Cholesterol Lowerer
A phase 1 trial tests RBD7022, a novel subcutaneous RNA-based therapy, for safety and dosing in adults with high LDL cholesterol.
Summary
RBD7022 is a new investigational drug developed by Suzhou Ribo Life Science, designed to lower LDL cholesterol through subcutaneous injection. This completed phase 1 study tested single and multiple ascending doses in participants with normal or elevated LDL cholesterol to assess safety, tolerability, and how the drug behaves in the body. The randomized, placebo-controlled design followed participants through dose escalation, with safety review committees deciding whether to advance to higher doses after evaluating each cohort. As an RNA-based medicine, RBD7022 belongs to a class of therapies that can silence genes responsible for cholesterol overproduction, potentially offering longer-lasting effects than daily pills. This early-phase work lays the groundwork for future efficacy studies and positions RBD7022 as a potential new option in the growing landscape of cholesterol-lowering biologics.
Detailed Summary
Cardiovascular disease remains the leading cause of death globally, and elevated LDL cholesterol is one of its most modifiable risk factors. While statins are the standard of care, many patients cannot tolerate them or fail to reach target LDL levels. Injectable RNA-based therapies — such as siRNA and antisense oligonucleotides — have opened a new frontier in lipid management, with drugs like inclisiran demonstrating that durable LDL reduction is achievable with infrequent dosing. RBD7022 represents the next candidate in this class, developed by Suzhou Ribo Life Science.
This phase 1 study, registered on ClinicalTrials.gov (NCT05912296), was a randomized, single-blind, placebo-controlled, single-center trial. It enrolled participants with either normal or elevated LDL cholesterol and evaluated subcutaneous administration of RBD7022 across both single ascending dose (SAD) and multiple ascending dose (MAD) phases. A safety review committee assessed all available safety data at each dose level before approving escalation to the next.
The trial has been listed as completed, suggesting that dose escalation was successfully conducted and that a safety and pharmacokinetic profile has been established. However, because the full results have not yet been published, specific data on tolerability, adverse events, drug exposure, or preliminary pharmacodynamic effects on LDL reduction are not publicly available from this abstract.
If RBD7022 follows the trajectory of related RNA therapies, it may offer prolonged LDL suppression with infrequent dosing — a major advantage for patient adherence. Early phase 1 safety data will determine whether larger efficacy trials are warranted.
Caveats are significant: this summary is based solely on the trial registration and abstract. No results data, adverse event rates, or pharmacokinetic parameters have been disclosed. The small phase 1 sample size and short observation window limit conclusions about long-term safety or clinical efficacy.
Key Findings
- RBD7022 is a novel subcutaneous RNA-based drug targeting LDL cholesterol, now completing phase 1 safety testing.
- The trial used a rigorous ascending dose design with safety committee review before each dose escalation.
- Both single and multiple dosing regimens were evaluated, covering a range of exposure levels.
- Participants included adults with both normal and elevated LDL, broadening the initial safety dataset.
- Completed status suggests dose escalation proceeded without stopping rules being triggered.
Methodology
Randomized, single-blind, placebo-controlled phase 1 study conducted at a single center. Participants received subcutaneous RBD7022 or placebo across sequential SAD and MAD cohorts, with dose escalation decisions made by a safety review committee after evaluating each cohort's safety data.
Study Limitations
This summary is based on the trial registration abstract only; no efficacy or detailed safety results have been published. Phase 1 trials are powered for safety, not efficacy, so no conclusions about LDL-lowering effectiveness can be drawn. The single-center design and small phase 1 sample size limit generalizability.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.